Rappta Therapeutics (Rappta), which is focused on developing first-in-class anti-cancer drugs reactivating protein phosphatase 2A (PP2A), has appointed Sunjeet Sawhney as Chief Executive Officer (CEO). Rappta’s Co-founder and Founding CEO Mikko Mannerkoski will move to be Chief Financial Officer (CFO) as planned. With over 20 years of experience in the industry, Sunjeet joins Rappta from Ipsen where…